HLA DRB1*1501 and intrathecal inflammation in multiple sclerosis

Tissue Antigens

Volumn 55, Issue 4, 2000, Pages 312-318

  Sellebjerg, Finn ^a,b   Jensen, J ^a   Madsen, H O ^a   Svejgaard, A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

CD4 T cells; Cerebrospinal fluid immunology; HLA DR; Immunogenetics; Multiple sclerosis

Indexed keywords

GELATINASE B; HLA DR ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR; HLA-DRB1 ANTIGEN;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; PRIORITY JOURNAL; T LYMPHOCYTE; CHEMISTRY; CYTOLOGY; FLOW CYTOMETRY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MYELIN SHEATH; T LYMPHOCYTE SUBPOPULATION;

ADULT; CEREBROSPINAL FLUID; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY TESTING; HLA-DR ANTIGENS; HUMANS; MALE; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELITIS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTE SUBSETS;

EID: 0033625559     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2000.550404.x     Document Type: Article

References (58)

1. 1. Sørensen TL, Ransohoff RM. Etiology and pathogenesis of multiple sclerosis. Semin Neurol 1998: 18: 287-94.
2. 2. Hillert J. Human leukocyte antigen studies in multiple sclerosis. Ann Neurol 1994: 36: S15-S17.
3. 3. Compston A. Genetic susceptibility to multiple sclerosis. In: Compston A, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerle H, eds. McAlpine's multiple sclerosis. London: Churchill Livingstone, 1998: 101-42.
4. 4. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990: 346: 183-7.
5. 5. Valli A, Sette A, Kappos L et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993: 91: 616-28.
6. 6. Wucherpfennig KW, Strominger JL. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. J Exp Med 1995: 181: 1597-601.
7. 7. Sellebjerg F, Frederiksen JL, Olsson T et al. Peptide specificity of anti-myelin basic protein antibodies in patients with acute optic neuritis and the HLA system. Scand J Immunol 1994: 39: 575-80.
8. 8. Madsen LS, Andersson EC, Jansson L et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 1999: 23: 343-7.
9. 9. Zipp F, Weber F, Huber S et al. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells. Ann Neurol 1995: 38: 723-30.
10. 10. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983: 13: 227-31.
11. 11. Poser CM. Onset symptoms of multiple sclerosis. J Neurol Neurosurg Psychiatry 1995: 58: 254-5.
12. 12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983: 33: 1444-52.
13. 13. Andersson M, Alvarez Cermeno J, Bernardi G et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994: 57: 897-902.
14. 14. Sellebjerg F, Christiansen M, Nielsen PM, Frederiksen JL. Cerebrospinal fluid measures of disease activity in multiple sclerosis. Multiple Sclerosis 1998: 4: 475-9.
15. 15. van Engelen BGM, Lamers KJB, Gabreels FJM, Wevers RA, van Geel WJA, Borm GF. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin Chem 1992: 38: 813-6.
16. 16. Blennow K, Fredman P, Wallin A et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 1993: 33: 129-33.
17. 17. Gijbeis K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory disorders. J Neuroimmunol 1992: 41: 29-34.
18. 18. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992: 39: 225-35.
19. 19. Sellebjerg F, Jensen J, Ryder LP. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis. J Neuroimmunol 1998: 84: 179-87.
20. 20. Frederiksen JL, Madsen HO, Ryder LP, Larsson HBW, Morling N, Svejgaard A. HLA typing in acute optic neuritis. Arch Neurol 1997: 54: 76-80.
21. 21. Ebers GC, Kukay K, Bulmjan DE et al. A full genome search in multiple sclerosis. Nat Genet 1996: 13: 472-6.
22. 22. The Multiple Sclerosis Study Group. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. Nat Genet 1996: 13: 469-71.
23. 23. Sawcer S, Jones HB, Feakes R et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996: 13: 464-8.
24. 24. Kuokkanen S, Gscwend M, Rioux JD et al. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet 1998: 61: 1379-87.
25. 25. Yaouanq J, Semana G, Eichenbaum S et al. Evidence for linkage disequilibrium between HLA-DRB1 gene and multiple sclerosis. The French research group on genetic susceptibility to MS. Science 1997: 276: 664-5.
26. 26. Haines JL, Terwedow HA, Burgess K et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum Mol Genet 1998: 7: 1229-34.
27. 27. Coraddu F, Sawcer S, Feakes R et al. HLA typing in the United Kingdom multiple sclerosis genome screen. Neurogenetics 1998: 2: 24-33.
28. 28. Stendahl L, Link H, Moller E, Norrby E. Relation between genetic markers and oligoclonal IgG in CSF in optic neuritis. J Neurol Sci 1976: 27: 93-8.
29. 29. Stendahl Brodin L, Link H, Moller E, Norrby E. Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF. Acta Neurol Scand 1979: 59: 297-308.
30. 30. Rumbach L, Tongio MM, Warter JM et al. HLA antigens in multiple sclerosis in Alsace. Biomed Pharmacother 1985: 39: 385-9.
31. 31. Söderström M, Lindqvist M, Hillert J, Käll T-B, Link H. Optic neuritis: findings on MR, CSF examination and HLA class II typing in 60 patients and results of a short-term follow-up. J Neurol 1994: 241: 391-7.
32. 32. Fukazawa T, Kikuchi S, Sasaki H et al. The significance of oligoclonal bands in multiple sclerosis in Japan: relevance of immunogenetic backgrounds. J Neurol Sci 1998: 158: 209-14.
33. 33. Weinshenker BG, Santrach P, Bissonet AS et al. Major histocompatibility complex class II alleles and the course and outcome of MS. Neurology 1998: 51: 742-7.
34. 34. Runmarker B, Martinsson T, Wahlström J, Andersen O. HLA and prognosis in multiple sclerosis. J Neurol 1994: 241: 385-90.
35. 35. Paemen L, Olsson T, Söderström M, Van Damme J, Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol 1994: 1: 55-63.
36. 36. Stuve O, Chabot S, Jung SS, Williams G, Yong VW. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by Interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 1997: 80: 38-46.
37. 37. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998: 21: 75-80.
38. 38. Leppert D, Ford J, Stabler G et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998: 121: 2327-34.
39. 39. Mun-Bryce S, Rosenberg GA. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 1998: 274: R1203-R1211.
40. 40. Konttinen YT, Bergroth V, Kinnunen E, Nordstrom D, Kouri T. Activated T lymphocytes in patients with multiple sclerosis in clinical remission. J Neurol Sci 1987: 81: 133-9.
41. 41. Fredrikson S, Karlsson Parra A, Olsson T, Link H. HLA-DR antigen expression on T cells from cerebrospinal fluid in multiple sclerosis and aseptic meningo-encephalitis. Clin Exp Immunol 1987: 68: 298-304.
42. 42. Oksaranta O, Tarvonen S, Ilonen J et al. Influx of nonactivated T lymphocytes into the cerebrospinal fluid during relapse of multiple sclerosis. Ann Neurol 1995: 38: 465-8.
43. 43. Sharief MK, Thompson EJ. The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann Neurol 1991: 29: 147-51.
44. 44. Paolino E, Fainardi E, Ruppi P et al. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry 1996: 60: 572-5.
45. 45. Söderström M, Jin Y-P, Hillert J, Link H. Optic neuritis. Prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998: 50: 708-14.
46. 46. Tumani H, Tourtellotte WW, Peter JB, Felgenhauer K. The Optic Neuritis Study Group X. Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. J Neurol Sci 1998: 155: 44-9.
47. 47. Fieschi C, Gasperini C, Ristori G et al. Diagnostic problems in "clinically definite" multiple sclerosis patients with normal CSF and multiple MRI abnormalities. Eur J Neurol 1994: 1: 127-33.
48. 48. Zeman AZ, Kidd D, McLean BN et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry 1996: 60: 27-30.
49. 49. Yachie A, Miyawaki T, Uwadana N, Ohzeki S, Taniguchi N. Sequential expression of T cell activation (Tac) antigen and Ia determinants on circulating human T cells after immunization with tetanus toxoid. J Immunol 1983: 131: 731-5.
50. 50. Correale J, McMillan M, Li S, McCarthy K, Le T, Weiner LP. Antigen presentation by autoreactive proteolipid protein peptide-specific T-cell clones from chronic progressive multiple sclerosis, patients: roles of co-stimulatory B7 molecues and IL-12. J Neuroimmunol 1997: 72: 27-43.
51. 51. Mannie MD, Rendall SK, Arrold PY, Nardella JP, White GA. Anergy-associated T-cell antigen presentation. A mechanism of infectious tolerance in experimental autoimmune encephalomyelitis. J Immunol 1996: 157: 1062-70.
52. 52. Van de Keere F, Tonegawa S CD4+ T cells prevent spontaneous experimental autoimmune encephalomyelitis in antimyelin basic protein T-cell receptor transgenic mice. J Exp Med 1998: 188: 1875-82.
53. 53. Olivares-Villagómez D, Wang Y, Lafaille JJ. Regulatory CD4+ T cells expressing endogenous T-cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous encephalomyelitis. J Exp Med 1998: 188: 1883-94.
54. 54. Illés Z, Kondo T, Yokoyama K, Ohashi T, Tabira T, Yamamura T. Identification of autoimmune T cells among in vivo expanded CD25+ T cells in multiple sclerosis. J Immunol 1999: 162: 1811-7.
55. 55. Lenardo M, Chan K-MC, Hornung F et al. Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999: 17: 221-53.
56. 56. Macchi B, Matteucci C, Nocentini U, Caltagirone C, Mastino A. Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. Neuroreport 1999: 10: 399-402.
57. 57. Zang YCQ, Kozovska MM, Hong J et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol 1999: 29: 1692-700.
58. 58. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T-cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998: 188: 287-96.